Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP

Experts conclude their discussion emphasizing the importance of integrative care and how providers can improve outcomes for their patients with fibromyalgia (FM).

Experts highlight current challenges in their practice treating patients with fibromyalgia (FM).

Experts discuss how they personalize treatments for patients with fibromyalgia (FM) and the importance of improving sleep in their approach.

Experts discuss the limited combination therapy options for the treatment of fibromyalgia (FM) and how to inform patients of prospective outcomes.

Experts discuss their step therapy approaches for the treatment of fibromyalgia (FM).

Experts discuss the long-term safety and efficacy of agents used for the treatment of fibromyalgia (FM).

Experts discuss the FDA approved agents duloxetine and pregabalin for the treatment of fibromyalgia (FM).

Experts discuss the FDA approved agent milnacipran for the treatment of fibromyalgia (FM).

Experts offer their clinical experience discussing how they utilize off label drugs in the treatment of fibromyalgia (FM).

Experts offer their clinical experience with nonsteroidal anti-inflammatory drugs (NSAID) in the treatment of fibromyalgia (FM).

Experts discuss their therapeutic approach and key agents utilized in the treatment of fibromyalgia (FM).

Experts discuss treatment options for fibromyalgia (FM) and how they utilize integrative care with patients.

Experts discuss which providers often diagnose fibromyalgia (FM) and how the burden of care has changed in recent years.

Experts discuss common comorbidities for patients with fibromyalgia (FM).

Experts offer clinical experience on why fibromyalgia (FM) is challenging to diagnose and how they rule out other chronic pain disorders.

Experts offer their clinical advice on what factors, outside of clinical therapies, may mitigate symptoms of fibromyalgia (FM).

Experts discuss the common characteristics of fibromyalgia (FM) and related symptoms.

Experts discuss known risk factors of fibromyalgia (FM).

Experts discuss the pathophysiology of fibromyalgia (FM) and how it relates to other chronic pain diseases.

Experts offer their clinical experience on why fibromyalgia (FM) is often misunderstood by patients and practitioners.

Wendy Wright, DNP, Kostas Botsoglou, MD, Daniel Clauw, MD, and Benjamin Natelson, MD, present an overview of symptoms and characteristics of fibromyalgia (FM).

Advanced practice practitioners share final pearls with their colleagues for the management of sleep disorders.

Dr Wendy Wright and Debra Davis comment on unmet needs in insomnia and other sleep disorders.

Advanced practice practitioners discuss how they assess treatment response and patient adherence in insomnia, and considerations for changing treatment.

Drs Wendy Wright and Debra Davis provide an overview of phase 3 trial data for the most recently FDA approved DORA, daridorexant, for the treatment of insomnia.

Advanced practice practitioners discuss dual orexin receptor antagonists (DORAs) suvorexant, lemborexant, and daridorexant for the treatment of sleep disorders.

Wendy Wright and Debra Davis provide an overview of pathways and neurotransmitters involved in sleep and wake cycles.

Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, and Madeline King, PharmD, BCIDP, provide insight on vaccine hesitancy among patients and the importance of increasing vaccine uptake to protect against SARS-CoV-2.

Rodney Rohde, SV, SM, MB (ASCP), FACSc, discusses the regression in combating antimicrobial resistance in the US because of the COVID-19 pandemic.

Jacinda Abdul-Mutakabbir, PharmD, comments on the importance of communicating the similarity of the bivalent booster vaccine safety profiles to patients.